Oruka surges as long-acting psoriasis drug shows early promise
BioPharma Dive
A therapy that works similarly to AbbVie s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
pharminent
April 27, 2026 (Last updated: April 28, 2026)
BioPharma Dive
A therapy that works similarly to AbbVie s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
